Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP): Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT)

Autor: Jim Zhong, Sarah Brown, Maria Serra, Pam Shuttleworth, Peter Bownes, Christopher Thompson, Rachel Reed, Kimberley Reeves, Michael Dubec, Damien McHugh, Cynthia Eccles, Robert Chuter, Yat Man Tsang, N Jane Taylor, Catharine West, David Buckley, Andrew Scarsbrook, Ananya Choudhury, Peter Hoskin, Ann Henry

Publikováno v: Zhong, J, Brown, S, Serra, M, Shuttleworth, P, Bownes, P, Thompson, C, Reed, R, Reeves, K, Dubec, M, McHugh, D, Eccles, C, Chuter, R, Tsang, Y M, Taylor, N J, West, C, Buckley, D, Scarsbrook, A, Choudhury, A, Hoskin, P & Henry, A 2022, ' Reirradiation Options for Previously Irradiated Prostate cancer (RO-PIP) : Feasibility study investigating toxicity outcomes following reirradiation with stereotactic body radiotherapy (SBRT) versus high-dose-rate brachytherapy (HDR-BT) ', BMJ Open, vol. 12, no. 11, 068580 . https://doi.org/10.1136/bmjopen-2022-068580

IntroductionRadiotherapy is the most common curative treatment for non-metastatic prostate cancer; however, up to 13% of patients will develop local recurrence within 10 years. Patients can undergo further and potentially curative treatment including

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::378a5906103a91a033272111e3e5079e
https://doi.org/10.1136/bmjopen-2022-068580